We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Screening Test Capable of Identifying 18 Early-Stage Cancers Could Be a Game Changer

By LabMedica International staff writers
Posted on 15 Jan 2024
Print article
Image: A groundbreaking cancer screening test marks a major step towards early detection (Photo courtesy of Novelna Inc.)
Image: A groundbreaking cancer screening test marks a major step towards early detection (Photo courtesy of Novelna Inc.)

Cancer, responsible for one-sixth of all global deaths, presents a formidable challenge, particularly because early detection is crucial for improving survival rates. However, current screening tests often fall short due to factors like invasiveness, cost, and limited accuracy in detecting early-stage diseases. In response to this challenge, researchers have now developed an innovative blood test that can identify 18 types of early-stage cancers across various major organs in the human body.

This groundbreaking test from Novelna Inc. (Palo Alto, CA, USA) leverages a gender-specific panel of 10 proteins, providing a significant advancement in the ongoing battle against cancer. The foundation for the test was laid by pioneering research that underscores the potential for a new class of cancer screening tests, promising enhanced accuracy, reduced cost, and a move towards personalized healthcare. In their research, the Novelna team analyzed plasma samples from 440 individuals, encompassing both healthy subjects and those diagnosed with 18 different early-stage solid tumors. They employed proximity extension assays to assess over 3,000 proteins—both high-abundance and low-abundance—in each sample. Subsequently, they applied a multi-layered statistical process to identify a select group of gender-specific proteins capable of detecting early-stage cancers and identifying their origin tissue with high accuracy.

This test's focus on gender-specific proteins allows for unparalleled sensitivity and specificity, acknowledging the unique biological differences in cancer development between men and women. Relying on protein markers rather than traditional genomic markers enhances the test's ability to detect various cancers accurately and promptly. The choice to limit the detection to 10 essential proteins considerably reduces the test's cost. Compared to Multi-Cancer Early Detection (MCED) tests, which can be priced around USD 1,000, Novelna's innovative test is expected to cost under USD 100, making early cancer detection more accessible for many.

With a sensitivity exceeding 80% for Stage I and II cancers—stages where patients are often asymptomatic—Novelna's test surpasses existing methods, which generally show less than 50% sensitivity for detecting cancers at early stages. This breakthrough holds the potential for reshaping public health strategies by integrating this plasma test into regular health check-ups. The high specificity of the test reduces the likelihood of false positives, and its affordability paves the way for broad implementation. The test could prove to be a game-changer in cancer screening by saving a significant number of lives.

"Our study represents a major leap in cancer screening, combining the precision of protein-based biomarkers with the efficiency of sex-specific analysis," said Dr. Ashkan Afshin, Founder of Novelna Inc. "We're not only looking at a more effective way of detecting cancer early but also at a cost-effective solution that can be implemented on a large scale."

"While further validation in larger population cohorts is necessary, we anticipate that our test will pave the way for more efficient, accurate, and accessible cancer screening," added Dr. Afshin.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The new versatile assay has the ability to measure both total and bioavailable cortisol from serum (Photo courtesy of Aarhus University)

Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases

The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Pathology

view channel
Image: The photoacoustic spectral response sensing instrument is based on low-cost laser diodes (Photo courtesy of Khan et al., doi 10.1117/1.JBO.29.1.017002)

Compact Photoacoustic Sensing Instrument Enhances Biomedical Tissue Diagnosis

The pursuit of precise and efficient diagnostic methods is a top priority in the constantly evolving field of biomedical sciences. A promising development in this area is the photoacoustic (PA) technique.... Read more

Industry

view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.